Jefferies has upgraded Edwards Lifesciences Corp (EW) from Hold to Buy, effective October 28, 2025. The stock is currently priced at $85.14.
This upgrade underscores a more optimistic outlook on the company's prospects, potentially reflecting enhanced fundamentals or improved business performance. Edwards Lifesciences, headquartered in Irvine, California, focuses on patient-centric medical innovations for heart disease and critical care monitoring. It employs approximately 15,800 individuals and has a market capitalisation of $47.9 billion.
The company, which went public on March 27, 2000, is known for its advancements in transcatheter heart valve replacement technologies. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), featuring systems such as the Edwards SAPIEN 3 and the Edwards SAPIEN 3 Ultra, as well as Transcatheter Mitral and Tricuspid Therapies (TMTT).
As of November 1, 2025, the analyst consensus for Edwards Lifesciences shows 10 Strong Buy, 18 Buy, and 15 Hold ratings, with no Sell or Strong Sell ratings. Recent earnings performance has also been notable, with the company reporting a Q3 2025 EPS of $0.67, exceeding estimates by 9.6%. Upcoming earnings reports are scheduled for April 20, 2026, and July 21, 2026, with estimated EPS of $0.70 and $0.74, respectively.
While analyst ratings provide valuable insights, they should be considered alongside a comprehensive evaluation of company fundamentals and market conditions.
This brief was generated from structured financial data and reviewed by the Investing Point editorial team. It is for informational purposes only and does not constitute investment advice.